Should the patent system for new medicines be abolished?
| Data(s) |
01/11/2007
|
|---|---|
| Formato |
488 - 490 |
| Identificador |
http://www.ncbi.nlm.nih.gov/pubmed/17952100 6100393 Clin Pharmacol Ther, 2007, 82 (5), pp. 488 - 490 http://hdl.handle.net/10161/6721 1532-6535 |
| Relação |
Clin Pharmacol Ther 10.1038/sj.clpt.6100393 |
| Tipo |
Journal Article |
| Cobertura |
United States |
| Idioma(s) |
ENG |
| Palavras-Chave | #Biomedical Research #Commerce #Cost-Benefit Analysis #Drug Costs #Drug Industry #Financing, Government #Humans #Insurance Coverage #Legislation, Drug #Orphan Drug Production #Patents as Topic #Pharmaceutical Preparations #Public Policy #United States |
